Moyamoya disease in a primarily white, Midwestern us population: Increased prevalence of autoimmune disease

Stroke

Volumn 44, Issue 7, 2013, Pages 1997-1999

  Bower, Regina S ^a   Mallory, Grant W ^a   Nwojo, MacAulay ^a   Kudva, Yogish C ^a   Flemming, Kelly D ^a   Meyer, Fredric B ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

immunology; moyamoya; pathogenesis; risk factor

Indexed keywords

ADULT; ANGIOGRAPHY; AORTA ARCH SYNDROME; ARTICLE; ASIAN; CARDIOVASCULAR RISK; CAUCASIAN; COMORBIDITY; ETHNICITY; FEMALE; GASTRITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MOYAMOYA DISEASE; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID DISEASE;

IMMUNOLOGY; MOYAMOYA; PATHOGENESIS; RISK FACTOR;

ADULT; AUTOIMMUNE DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 1; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MIDWESTERN UNITED STATES; MOYAMOYA DISEASE; PREVALENCE; THYROID DISEASES; YOUNG ADULT;

EID: 84879930741     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000307     Document Type: Article

References (15)

1. Suzuki J, Takaku A. Cerebrovascular moyamoya disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969;20:288-299
2. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med 2009;360:1226-1237
3. Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, et al. Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg 1997;99 suppl 2:S1-S5
4. Goto Y, Yonekawa Y. Worldwide distribution of moyamoya disease. Neurol Med Chir (Tokyo) 1992;32:883-886
5. Uchino K, Johnston SC, Becker KJ, Tirschwell DL. Moyamoya disease in Washington State and California. Neurology 2005;65:956-958
6. Hallemeier CL, Rich KM, Grubb RL Jr, Chicoine MR, Moran CJ, Cross DT III, et al. Clinical features and outcome in North American adults with moyamoya phenomenon. Stroke. 2006;37:1490-1496
7. Starke RM, Crowley RW, Maltenfort M, Jabbour PM, Gonzalez LF, Tjoumakaris SI, et al. Moyamoya disorder in the United States. Neurosurgery. 2012;71:93-99
8. Achrol AS, Guzman R, Lee M, Steinberg GK. Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus. 2009;26:E4.
9. Kim SJ, Heo KG, Shin HY, Bang OY, Kim GM, Chung CS, et al. Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease: a prospective study. Stroke. 2010;41:173-176
10. El Ramahi KM, Al Rayes HM. Systemic lupus erythematosus associated with moyamoya syndrome. Lupus. 2000;9:632-636
11. National Diabetes Information Clearinghouse (NDIC), A service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH). National Diabetes Statistics, 2011. http://www.diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed July 15, 2012.
12. Division for Heart Disease and Stroke. Prevention, Centers for Disease Control and Prevention. Cholesterol Fact Sheet, 2012. http://www.cdc.gov/ dhdsp/data-statistics/fact-sheets/fs-cholesterol.htm. Accessed October 20, 2012.
13. Schiller JS, Lucas JW, Ward BW, Peregoy JA. Summary health statistics for U.S. Adults: National health interview survey, 2010. Vital Health Stat. 2012;10:1-207
14. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 2003;2:119-125
15. Ogawa K, Nagahiro S, Arakaki R, Ishimaru N, Kobayashi M, Hayashi Y. Anti-Alpha-fodrin autoantibodies in Moyamoya disease. Stroke. 2003;34:e244-e246.